Benign mesenchymal stromal cells in human sarcomas

Clinical Cancer Research

Volumn 16, Issue 23, 2010, Pages 5630-5640

  Morozov, Alexei ^a,b   Downey, Robert J ^a   Healey, John ^a   Moreira, Andre L ^a   Lou, Emil ^a   Franceschino, Anna ^a   Dogan, Yildirim ^a   Leung, Roland ^a   Edgar, Mark ^a   LaQuaglia, Michael ^a   Maki, Robert G ^a   Moore, Malcolm A S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ImClone Systems   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; CD146 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CELL MARKER; ENDOGLIN; HERMES ANTIGEN; MATRIGEL; THY 1 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BENIGN TUMOR; BONE; CANCER CELL CULTURE; CARCINOGENESIS; CARTILAGE; CELL DIFFERENTIATION; CELL FUNCTION; CELL STRAIN; CELL STRAIN A 673; CELL STRAIN DDLS 8817; CELL STRAIN U2OS; CELL STRUCTURE; COCULTURE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MESENCHYMAL STROMAL CELL; MESENCHYME CELL; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SARCOMA; SARCOMA CELL; STROMA CELL; TUMOR XENOGRAFT;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SEPARATION; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; SARCOMA; STROMAL CELLS; TRANSPLANTATION, HETEROLOGOUS;

EID: 78650366051     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2886     Document Type: Article

References (50)

1. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al. SEER Cancer Statistics Review, 1975-2005. National Cancer Institute. Bethesda, MD; 2008. Available from: http://seer.cancer.gov/csr/1975-2005/. Based on November 2007 SEER data submission.
2. Fletcher CDM, Unni KK, Mertens F, World Health Organization, International Agency for Research on Cancer. Pathology and Genetics of Tumours of Soft Tissue and Bone. Oxford: IARC Press; 2002.
3. Wunder JS, Nielsen TO, Maki RG, O'Sullivan B, Alman BA. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 2007;8:513-24. (Pubitemid 46823060)
4. Mackall CL, Meltzer PS, Helman LJ. Focus on sarcomas. Cancer Cell 2002;2:175-8.
5. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005;7:393-5. (Pubitemid 41671625)
6. Castro-Malaspina H, Gay RE, Resnick G, Kapoor N, Meyers P, Chiarieri D, et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 1980;56:289-301.
7. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007;11:421-9.
8. Riggi N, Cironi L, Provero P, Suvà ML, Stehle JC, Baumer K, et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 2006;66:7016-23.
9. Riggi N, Suva ML, Suva D, Cironi L, Provero P, Tercier S, et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008;68:2176-85. (Pubitemid 351521790)
10. Matushansky I, Hernando E, Socci ND, Matos T, Mills J, Edgar MA, et al. A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol 2008;172:1069-80.
11. Berman SD, Calo E, Landman AS, Danielian PS, Miller ES, West JC, et al. Metastatic osteosarcoma induced by inactivation of rb and p53 in the osteoblast lineage. Proc Natl Acad Sci USA 2008.
12. da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008.
13. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008;3:301-13.
14. Gregory CA, Prockop DJ. Fundamentals of culture and characterization of mesenchymal stem/progenitor cells (MSCs) from bone marrow stroma. In:Freshney RI, Stacey G, Auerbach JM, editors. Culture of Human Stem Cells. Hoboken, NJ: Wiley-Interscience; 2007. p. 207.
15. Nagayama M, Uchida T, Gohara K. Temporal and spatial variations of lipid droplets during adipocyte division and differentiation. J Lipid Res 2007;48:9-18.
16. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005;174:6477-89.
17. McGonigle S, Shifrin V. In vitro assay of angiogenesis: inhibition of capillary tube formation. In: Current Protocols in Pharmacology . New York: Wiley; 2008. p. 12.12.1-7.
18. MacKenzie KL, Franco S, Naiyer AJ, May C, Sadelain M, Rafii S, et al. Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras. Oncogene 2002;21:4200-11.
19. Laxa B, Angeles C, Brill E, Lagos M, O'Connor R, Decarolis P, et al. High throughput compound screening identifies new differentiation-based therapies for dedifferentiated liposarcoma (DDLS). 62nd Annual Cancer Symposium of Society of Surgical Oncology. Ann Surg Oncol 2009;16:14. Abstract 40.
20. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7.
21. Ladanyi M. Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene 2001;20:5755-62.
22. Weaver J, Downs-Kelly E, Goldblum JR, Turner S, Kulkarni S, Tubbs RR, et al. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol 2008;21:943-9.
23. Bagley RG, Rouleau C, Morgenbesser SD, Weber W, Cook BP, Shankara S, et al. Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy. Microvasc Res 2006;71:163-74.
24. Rouleau C, Curiel M, Weber W, Smale R, Kurtzberg L, Mascarello J, et al. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clin Cancer Res 2008;14:7223-36.
25. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000;60:1388-93.
26. Kalinski T, Sel S, Kouznetsova I, Ropke M, Roessner A. Heterogeneity of angiogenesis and blood vessel maturation in cartilage tumors. Pathol Res Pract 2009;205:339-45.
27. Shih IM, Wang TL, Westra WH. Diagnostic and biological implications of mel-CAM expression in mesenchymal neoplasms. Clin Cancer Res 1996;2:569-75.
28. Crisan M, Chen CW, Corselli M, Andriolo G, Lazzari L, Peault B. Perivascular multipotent progenitor cells in human organs. Ann N Y Acad Sci 2009;1176:118-23.
29. Tripodo C, DiBernardo A, Ternullo MP, Guarnotta C, Porcasi R, Ingrao S, et al. CD146(+) bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis. Haematologica 2009;94:127-30.
30. Yao X, Qian CN, Zhang ZF, Tan MH, Kort EJ, Yang XJ, et al. Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications. Clin Cancer Res 2007;13:161-9.
31. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 2008;14:1931-7.
32. Cailleau RM. Old and new problems in human tumor cell cultivation. In:Fogh J, editor. Human Tumor Cells In Vitro. New York: Plenum Press; 1975. p. 79.
33. Thompson FH. Cytogenetics of human solid tumors. In:Barch MJ, et al., editors. The ACT Cytogenetics Laboratory Manual. 2nd ed. New York: Raven Press; 1997. p. 625.
34. Sethi J, Hirshaut Y, Hajdu SI, Clements LG. Growing human sarcomas in culture. Cancer 1977;40:744-55.
35. Hu M, Nicolson GL, Trent JC II, Yu D, Zhang L, Lang A, et al. Characterization of 11 human sarcoma cell strains: evaluation of cytogenetics, tumorigenicity, metastasis, and production of angiogenic factors. Cancer 2002;95:1569-76.
36. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A 1997;94:237-41.
37. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A 1999;96:3951-6.
38. Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev 2009;19:67-73.
39. Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet 2009;25:30-8.
40. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-63.
41. Kidd S, Spaeth E, Klopp A, Andreeff M, Hall B, Marini FC. The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy 2008;10:657-67.
42. Brune JC, Tormin A, Bauer U, Neumann U, Rissler P, Brosjo O, et al. Mesenchymal stromal cells (MSC) isolated from human osteosarcomas show a high progenitor cell frequency, typical MSC morphology, surface marker profile, and differentiation capacity, and they are considerably affected by tyrosine kinase inhibitors in vitro. ASH Annu Meeting Abstr 2008;112:1360.
43. Lang FF, Gumin J, Amano T, Hata N, Heimberger AB, Marini F, et al. Tumor-derived mesenchymal stem cells in human gliomas: isolation and biological properties. J Clin Oncol (Meeting Abstr) 2008;26:2001.
44. Suva ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, et al. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 2009;69:1776-81.
45. Reddy K, Zhou Z, Schadler K, Jia SF, Kleinerman ES. Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels. Mol Cancer Res 2008;6:929-36.
46. Wu C, Wei Q, Utomo V, Nadesan P, Whetstone H, Kandel R, et al. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res 2007;67:8216-22.
47. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005;7:513-20.
48. Wels J, Kaplan RN, Rafii S, Lyden D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev 2008;22:559-74.
49. Mendelson DS, Gordon MS, Rosen LS, Hurwitz H, Wong MK, Adams BJ, et al. Phase I study of TRC105 (anti-CD105 [endoglin] antibody) therapy in patients with advanced refractory cancer. J Clin Oncol (Meeting Abstracts) 2010;28:3013.
50. Benassi MS, Pazzaglia L, Chiechi A, Alberghini M, Conti A, Cattaruzza SA, et al. NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients. J Orthop Res 2009;27:135-40.